Temporally Complex Inflammatory Networks in an Animal Model Reveal Signatures for Interstitial Cystitis and Bladder Pain Syndrome Phenotype

Overview

Journal Neurourol Urodyn

Date 2023 Aug 17

PMID 37587846

Authors

Ashti M Shah

Yoram Vodovotz

Naoki Yoshimura

Christopher J Chermansky

Jocelyn Fitzgerald

Pradeep Tyagi

Affiliations

Soon will be listed here.

Abstract

Introduction And Objective: Interstitial cystitis and bladder pain syndrome (IC/BPS) presents with symptoms of debilitating bladder pain and is typically a diagnosis of exclusion. The cystoscopic detection of Hunner's lesions increases the likelihood of detecting tissue inflammation on bladder biopsy and increases the odds of therapeutic success with anti-inflammatory drugs. However, the identification of this subgroup remains challenging with the current lack of surrogate biomarkers of IC/BPS. On the path towards identifying biomarkers of IC/BPS, we modeled the dynamic evolution of inflammation in an experimental IC/BPS rodent model using computational biological network analysis of inflammatory mediators (cytokines and chemokines) released into urine. The use of biological network analysis allows us to identify urinary proteins that could be drivers of inflammation and could therefore serve as therapeutic targets for the treatment of IC/BPS.

Methods: Rats subjected to cyclophosphamide (CYP) injection (150 mg/kg) were used as an experimental model for acute IC/BPS (n = 8). Urine from each void was collected from the rats over a 12-h period and was assayed for 13 inflammatory mediators using Luminex™. Time-interval principal component analysis (TI-PCA) and dynamic network analysis (DyNA), two biological network algorithms, were used to identify biomarkers of inflammation characteristic of IC/BPS over time.

Results: Compared to vehicle-treated rats, nearly all inflammatory mediators were elevated significantly (p < 0.05) in the urine of CYP treated rats. TI-PCA highlighted that GRO-KC, IL-5, IL-18, and MCP-1 account for the greatest variance in the inflammatory response. At early time points, DyNA indicated a positive correlation between IL-4 and IL-1β and between TNF-α and IL-1β. Analysis of TI-PCA and DyNA at later time points showed the emergence of IL-5, IL-6, and IFNγ as additional key mediators of inflammation. Furthermore, DyNA network complexity rose and fell before peaking at 9.5 h following CYP treatment. This pattern of inflammation may mimic the fluctuating severity of inflammation associated with IC/BPS flares.

Conclusions: Computational analysis of inflammation networks in experimental IC/BPS analysis expands on the previously accepted inflammatory signatures of IC by adding IL-5, IL-18, and MCP-1 to the prior studies implicating IL-6 and GRO as IC/BPS biomarkers. This analysis supports a complex evolution of inflammatory networks suggestive of the rise and fall of inflammation characteristic of IC/BPS flares.

Citing Articles

Divergent histopathological and molecular patterns in chemically induced interstitial cystitis/bladder pain syndrome rat models.

Chang Y, Yu C, Dong C, Chen S, Sung W Sci Rep. 2024; 14(1):16134.

PMID: 38997336 PMC: 11245554. DOI: 10.1038/s41598-024-67162-y.

SWOT and Root Cause Analyses of Antimicrobial Resistance to Oral Antimicrobial Treatment of Cystitis.

Tyagi P, Tyagi S, Stewart L, Glickman S Antibiotics (Basel). 2024; 13(4).

PMID: 38667004 PMC: 11047466. DOI: 10.3390/antibiotics13040328.

References

Smaldone M, Vodovotz Y, Tyagi V, Barclay D, Philips B, Yoshimura N . Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology. 2008; 73(2):421-6. PMC: 2662614. DOI: 10.1016/j.urology.2008.07.031. View

Kono J, Ueda M, Sengiku A, Suadicani S, Woo J, Kobayashi T . Flavonoid Nobiletin Attenuates Cyclophosphamide-Induced Cystitis in Mice through Mechanisms That Involve Inhibition of IL-1β Induced Connexin 43 Upregulation and Gap Junction Communication in Urothelial Cells. Int J Mol Sci. 2022; 23(9). PMC: 9102543. DOI: 10.3390/ijms23095037. View

Tudrej K, Piecha T, Kozlowska-Wojciechowska M . Role of NLRP3 inflammasome in the development of bladder pain syndrome interstitial cystitis. Ther Adv Urol. 2019; 11:1756287218818030. PMC: 6329030. DOI: 10.1177/1756287218818030. View

Moldwin R, Nursey V, Yaskiv O, Dalvi S, Macdonald E, Funaro M . Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome. J Transl Med. 2022; 20(1):97. PMC: 8862517. DOI: 10.1186/s12967-022-03236-7. View

Rosamilia A, Cann L, Dwyer P, Scurry J, Rogers P . Bladder microvasculature in women with interstitial cystitis. J Urol. 1999; 161(6):1865-70. View

Homma Y, Akiyama Y, Tomoe H, Furuta A, Ueda T, Maeda D . Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol. 2020; 27(7):578-589. DOI: 10.1111/iju.14234. View

Jiang Y, Jhang J, Hsu Y, Ho H, Wu Y, Kuo H . Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Sci Rep. 2021; 11(1):914. PMC: 7806856. DOI: 10.1038/s41598-020-80131-5. View

Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N . Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. Int Urogynecol J. 2018; 29(7):961-966. DOI: 10.1007/s00192-017-3547-5. View

Johansson S, Fall M . Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990; 143(6):1118-24. DOI: 10.1016/s0022-5347(17)40201-1. View

10.

Kuret T, Peskar D, Kreft M, Erman A, Veranic P . Comprehensive transcriptome profiling of urothelial cells following TNFα stimulation in an interstitial cystitis/bladder pain syndrome model. Front Immunol. 2022; 13:960667. PMC: 9421144. DOI: 10.3389/fimmu.2022.960667. View

11.

Mattila J . Vascular immunopathology in interstitial cystitis. Clin Immunol Immunopathol. 1982; 23(3):648-55. DOI: 10.1016/0090-1229(82)90327-0. View

12.

Walker S, Zambon J, Andersson K, Langefeld C, Matthews C, Badlani G . Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2017; 198(2):369-375. DOI: 10.1016/j.juro.2017.02.022. View

13.

Girard B, Campbell S, Vizzard M . Stress-induced symptom exacerbation: Stress increases voiding frequency, somatic sensitivity, and urinary bladder NGF and BDNF expression in mice with subthreshold cyclophosphamide (CYP). Front Urol. 2023; 3. PMC: 10558155. DOI: 10.3389/fruro.2023.1079790. View

14.

Elbadawi A, Light J . Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol Int. 1996; 56(3):137-62. DOI: 10.1159/000282832. View

15.

Birder L, Andersson K . Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome. Int Neurourol J. 2018; 22(Suppl 1):S3-9. PMC: 5798638. DOI: 10.5213/inj.1835062.531. View

16.

Teruel C, Garrido E, Mesonero F . Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther. 2016; 7(1):78-90. PMC: 4734957. DOI: 10.4292/wjgpt.v7.i1.78. View

17.

Hohlbrugger G, Frauscher F, Strasser H, Stenzl A, Bartsch G . Evidence for the autoregulation of vesical circulation by intravesical potassium chloride and distension in the normal human bladder. BJU Int. 2000; 85(4):412-5. DOI: 10.1046/j.1464-410x.2000.00519.x. View

18.

Parsons J, Kurth K, Sant G . Epidemiologic issues in interstitial cystitis. Urology. 2007; 69(4 Suppl):5-8. DOI: 10.1016/j.urology.2006.05.050. View

19.

Zamora R, Chavan S, Zanos T, Simmons R, Billiar T, Vodovotz Y . Spatiotemporally specific roles of TLR4, TNF, and IL-17A in murine endotoxin-induced inflammation inferred from analysis of dynamic networks. Mol Med. 2021; 27(1):65. PMC: 8223370. DOI: 10.1186/s10020-021-00333-z. View

20.

Lv J, Huang Y, Zhu S, Yang G, Zhang Y, Leng J . MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain syndrome in rat models. Mediators Inflamm. 2012; 2012:358184. PMC: 3459284. DOI: 10.1155/2012/358184. View